ATE414720T1 - Rationell entworfene antikörper - Google Patents
Rationell entworfene antikörperInfo
- Publication number
- ATE414720T1 ATE414720T1 AT04077554T AT04077554T ATE414720T1 AT E414720 T1 ATE414720 T1 AT E414720T1 AT 04077554 T AT04077554 T AT 04077554T AT 04077554 T AT04077554 T AT 04077554T AT E414720 T1 ATE414720 T1 AT E414720T1
- Authority
- AT
- Austria
- Prior art keywords
- antibodies
- rationally designed
- fragments
- designed antibodies
- terminal
- Prior art date
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25144800P | 2000-12-05 | 2000-12-05 | |
US28888901P | 2001-05-04 | 2001-05-04 | |
US29406801P | 2001-05-29 | 2001-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE414720T1 true ATE414720T1 (de) | 2008-12-15 |
Family
ID=27400449
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01985007T ATE320450T1 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
AT05076105T ATE544785T1 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
AT04077554T ATE414720T1 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01985007T ATE320450T1 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
AT05076105T ATE544785T1 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
Country Status (11)
Country | Link |
---|---|
US (3) | US7482435B2 (de) |
EP (4) | EP1370589B1 (de) |
AT (3) | ATE320450T1 (de) |
AU (2) | AU2002234001B2 (de) |
CA (1) | CA2436671C (de) |
CY (1) | CY1112639T1 (de) |
DE (2) | DE60136656D1 (de) |
DK (1) | DK1642910T3 (de) |
ES (3) | ES2316919T3 (de) |
PT (1) | PT1642910E (de) |
WO (1) | WO2002046238A2 (de) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU773891C (en) | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
AU2003295623B2 (en) * | 2000-12-05 | 2008-06-05 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
ATE320450T1 (de) * | 2000-12-05 | 2006-04-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
EP1545608A4 (de) * | 2002-06-28 | 2006-09-13 | Centocor Inc | Ch1-deletierte säugetier-mimetikörper, zusammensetzungen, verfahren und anwendungen |
US20060127404A1 (en) * | 2003-09-30 | 2006-06-15 | Chichi Huang | Hinge core mimetibodies, compositions, methods and uses |
UA89481C2 (uk) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US20070116710A1 (en) * | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
BR122017024057B8 (pt) | 2006-03-15 | 2021-05-25 | Alexion Pharma Inc | anticorpo que se liga à c5 e composição farmacêutica compreendendo dito anticorpo e um veículo farmaceuticamente aceitável |
EP2102339A2 (de) * | 2007-01-12 | 2009-09-23 | Sea Lane Biotechnologies,llc. | Kombinatorische bibliotheken aus konformationseingeschränkten polypeptidsequenzen |
US20090022729A1 (en) * | 2007-04-13 | 2009-01-22 | Nigel Mackman | Methods and compositions for treating cardiac dysfunctions |
US20090054332A1 (en) * | 2007-06-21 | 2009-02-26 | Conjuchem Biotechnologies, Inc. | Thombopoietin peptide conjugates |
DK2894165T3 (da) | 2008-11-10 | 2023-03-20 | Alexion Pharma Inc | Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser |
KR20110122846A (ko) * | 2009-02-24 | 2011-11-11 | 알렉시온 파마슈티칼스, 인코포레이티드 | 치료용 tpo/epo 모방 펩티드를 포함하는 항체 |
MX349662B (es) | 2010-07-22 | 2017-08-08 | Univ California | Anticuerpos de antigenos antitumorales y metodos de uso. |
TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
SG10201509499RA (en) | 2010-11-19 | 2015-12-30 | Eisai R&D Man Co Ltd | Neutralizing anti-ccl20 antibodies |
PL2928921T3 (pl) | 2012-12-05 | 2021-06-28 | Novartis Ag | Kompozycje i sposoby dla przeciwciał celujących w epo |
BR122020019190B1 (pt) | 2013-08-07 | 2023-11-21 | Alexion Pharmaceuticals, Inc. | Métodos para monitorar a responsividade de um indivíduo ao tratamento com um inibidor do complemento, métodos para diagnosticar um indivíduo tendo ou com risco de desenvolver síndrome urêmica hemolítica atípica (ahus) e uso de um kit de diagnóstico para diagnosticar ahus |
JP2018508481A (ja) | 2015-02-02 | 2018-03-29 | ザ ユニバーシティ オブ バーミンガム | 複数のt細胞エピトープを有する標的化部分ペプチドエピトープ複合体 |
WO2017025928A2 (en) | 2015-08-12 | 2017-02-16 | Novartis Ag | Methods of treating ophthalmic disorders |
US10144768B2 (en) * | 2015-12-04 | 2018-12-04 | Novartis Ag | Antibody cytokine engrafted compositions and methods of use for immunoregulation |
GB2562933B (en) | 2016-01-08 | 2022-06-29 | Maxion Therapeutics Ltd | Binding members with altered diversity scaffold domains |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
WO2018215936A1 (en) | 2017-05-24 | 2018-11-29 | Novartis Ag | Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
US20230331827A1 (en) | 2017-07-12 | 2023-10-19 | Maxion Therapeutics Limited | Potassium channel inhibitors |
CN108623681B (zh) * | 2018-05-04 | 2019-05-24 | 珠海泰诺麦博生物技术有限公司 | 一种抗破伤风毒素的中和抗体及应用 |
US11066469B2 (en) | 2019-06-12 | 2021-07-20 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3382317D1 (de) * | 1982-03-15 | 1991-07-25 | Schering Corp | Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer. |
GB8308235D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4783330A (en) * | 1984-11-15 | 1988-11-08 | New England Medical Center Hospitals, Inc. | Monoclonal antibodies to activated platelets |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8720833D0 (en) * | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5965405A (en) * | 1988-04-16 | 1999-10-12 | Celltech Limited | Method for producing Fv fragments in eukaryotic cells |
US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US20020086843A1 (en) * | 1989-03-01 | 2002-07-04 | Daiichi Pure Chemicals Co., Ltd. | Physiologically active polypeptide and DNA |
US5260417A (en) * | 1989-04-03 | 1993-11-09 | Genetics Institute, Inc. | Megakaryocyte growth promoting activity protein |
US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE69129154T2 (de) * | 1990-12-03 | 1998-08-20 | Genentech, Inc., South San Francisco, Calif. | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
ATE196548T1 (de) * | 1991-05-10 | 2000-10-15 | Genentech Inc | Auswählen von agonisten und antagonisten von liganden |
IL102490A0 (en) * | 1991-07-15 | 1993-01-14 | Wellcome Found | Production of antibodies |
JP2665850B2 (ja) * | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | hBNPのC端を認識するモノクロ−ナル抗体 |
AU4190893A (en) * | 1992-07-17 | 1994-01-20 | Suntory Limited | Megakaryocyte differentiation factor |
AU6235294A (en) * | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing polypeptide binding sites |
CA2174532A1 (en) * | 1993-10-19 | 1995-04-27 | Carlos F. Barbas | Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5598435A (en) * | 1993-12-23 | 1997-01-28 | British Telecommunications Public Limited Company | Digital modulation using QAM with multiple signal point constellations not equal to a power of two |
US5919758A (en) * | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
WO1995029690A1 (en) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
US5885574A (en) * | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5593666A (en) * | 1994-08-16 | 1997-01-14 | The University Of Tennessee Research Corp. | Methods and compositions for treating thrombocytopenia |
DE19513676A1 (de) * | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
EP1961760A3 (de) * | 1995-06-07 | 2008-09-03 | Glaxo Group Limited | Peptide und Verbindungen, die einen Thrombopoietin-Rezeptor binden |
WO1996040189A1 (en) * | 1995-06-07 | 1996-12-19 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
EP2292662B1 (de) * | 1996-03-04 | 2014-04-23 | Scios Inc. | Testverfahren und Reagenzien zur Quantifizierung von hBNP |
US5932546A (en) * | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6737249B1 (en) * | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
US6342220B1 (en) * | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
JP2002507544A (ja) * | 1997-11-14 | 2002-03-12 | ユーロ−セルティーク,エス.エイ. | 抗イディオタイプ応答を引き出す能力が増強された改変型の抗体 |
AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6660843B1 (en) * | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
AU773891C (en) * | 1998-10-23 | 2005-02-17 | Kirin-Amgen Inc. | Dimeric thrombopoietin peptide mimetics binding to MP1 receptor and having thrombopoietic activity |
JP2002544123A (ja) * | 1999-04-14 | 2002-12-24 | スミスクライン・ビーチャム・コーポレイション | エリトロポイエチン受容体抗体 |
ATE320450T1 (de) * | 2000-12-05 | 2006-04-15 | Alexion Pharma Inc | Rationell entworfene antikörper |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
WO2002078612A2 (en) * | 2001-04-02 | 2002-10-10 | Euro-Celtique S.A. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
-
2001
- 2001-12-05 AT AT01985007T patent/ATE320450T1/de not_active IP Right Cessation
- 2001-12-05 EP EP01985007A patent/EP1370589B1/de not_active Expired - Lifetime
- 2001-12-05 AU AU2002234001A patent/AU2002234001B2/en not_active Ceased
- 2001-12-05 DK DK05076105.5T patent/DK1642910T3/da active
- 2001-12-05 DE DE60136656T patent/DE60136656D1/de not_active Expired - Lifetime
- 2001-12-05 AU AU3400102A patent/AU3400102A/xx active Pending
- 2001-12-05 ES ES04077554T patent/ES2316919T3/es not_active Expired - Lifetime
- 2001-12-05 US US10/006,593 patent/US7482435B2/en not_active Expired - Fee Related
- 2001-12-05 DE DE60118023T patent/DE60118023T2/de not_active Expired - Lifetime
- 2001-12-05 CA CA2436671A patent/CA2436671C/en not_active Expired - Fee Related
- 2001-12-05 ES ES01985007T patent/ES2258558T3/es not_active Expired - Lifetime
- 2001-12-05 AT AT05076105T patent/ATE544785T1/de active
- 2001-12-05 PT PT05076105T patent/PT1642910E/pt unknown
- 2001-12-05 ES ES05076105T patent/ES2380367T3/es not_active Expired - Lifetime
- 2001-12-05 EP EP04077553A patent/EP1498429A3/de not_active Withdrawn
- 2001-12-05 EP EP04077554A patent/EP1589034B1/de not_active Expired - Lifetime
- 2001-12-05 EP EP05076105A patent/EP1642910B1/de not_active Expired - Lifetime
- 2001-12-05 WO PCT/US2001/047656 patent/WO2002046238A2/en not_active Application Discontinuation
- 2001-12-05 AT AT04077554T patent/ATE414720T1/de not_active IP Right Cessation
-
2009
- 2009-01-26 US US12/321,828 patent/US8771932B2/en not_active Expired - Fee Related
-
2012
- 2012-03-12 CY CY20121100251T patent/CY1112639T1/el unknown
-
2014
- 2014-04-29 US US14/264,975 patent/US9409964B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1498429A2 (de) | 2005-01-19 |
US8771932B2 (en) | 2014-07-08 |
PT1642910E (pt) | 2012-03-22 |
ATE544785T1 (de) | 2012-02-15 |
EP1642910A1 (de) | 2006-04-05 |
CY1112639T1 (el) | 2016-02-10 |
DE60136656D1 (de) | 2009-01-02 |
DE60118023D1 (de) | 2006-05-11 |
EP1370589B1 (de) | 2006-03-15 |
ES2316919T3 (es) | 2009-04-16 |
EP1370589A2 (de) | 2003-12-17 |
US7482435B2 (en) | 2009-01-27 |
ATE320450T1 (de) | 2006-04-15 |
AU2002234001B2 (en) | 2008-05-01 |
CA2436671C (en) | 2015-02-03 |
CA2436671A1 (en) | 2002-06-13 |
US9409964B2 (en) | 2016-08-09 |
DK1642910T3 (da) | 2012-05-07 |
EP1642910B1 (de) | 2012-02-08 |
WO2002046238A2 (en) | 2002-06-13 |
EP1589034A2 (de) | 2005-10-26 |
EP1589034B1 (de) | 2008-11-19 |
US20150004700A1 (en) | 2015-01-01 |
AU3400102A (en) | 2002-06-18 |
WO2002046238A3 (en) | 2003-07-10 |
ES2258558T3 (es) | 2006-09-01 |
EP1498429A3 (de) | 2005-08-03 |
US20100041012A1 (en) | 2010-02-18 |
DE60118023T2 (de) | 2006-12-28 |
ES2380367T3 (es) | 2012-05-11 |
US20030049683A1 (en) | 2003-03-13 |
EP1589034A3 (de) | 2005-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414720T1 (de) | Rationell entworfene antikörper | |
WO2005060642A3 (en) | Rationally designed antibodies | |
WO2004050017A3 (en) | Rationally designed antibodies | |
WO2005082004A3 (en) | Rationally designed antibodies having a domain-exchanged scaffold | |
HK1109160A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
ID27784A (id) | Peptida-peptida penghambat hepatitis c | |
IL160001A0 (en) | Peptide based multimeric targeted contrast agents and methods for the preparation thereof | |
DE60032486D1 (de) | Prion protein peptide und deren verwendung | |
IL195649A0 (en) | Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same | |
ATE455561T1 (de) | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
AU2002308348A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
NO20073914L (no) | Biologisk aktive peptider | |
FR2810985B1 (fr) | Peptides lineaires amphipathiques et les compositions les contenant | |
WO2004108078A3 (en) | Rationally designed antibodies | |
Critical Care Society of South Africa Working Group | Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated) | |
CY1113344T1 (el) | Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων | |
ATA19362001A (de) | Nukleinsäure bindende peptide und die verwendung derartiger peptide in pharmazeutischen präparaten | |
HK1044796A1 (zh) | 為新穎兼平切的可卡因和安菲他明調節轉錄物(cart)蛋白及其相應的平切的可卡因和安菲他明調節轉錄物縮多氨酸進行編碼的核酸及該核酸的醫療和診斷用途 | |
ITRM960808A1 (it) | Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia | |
IT1254976B (it) | Fattori chemiotattici |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |